Penicillamine should not be used as initial therapy in Wilson's disease
- 1 July 1999
- journal article
- editorial
- Published by Wiley in Movement Disorders
- Vol. 14 (4) , 551-554
- https://doi.org/10.1002/1531-8257(199907)14:4<551::aid-mds1002>3.0.co;2-s
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Treatment of Wilson Disease With Ammonium TetrathiomolybdateArchives of Neurology, 1996
- Treatment of Wilson's Disease With Ammonium TetrathiomolybdateArchives of Neurology, 1994
- Initial Therapy of Patients With Wilson's Disease With TetrathiomolybdateArchives of Neurology, 1991
- Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimensHepatology, 1987
- Worsening of Neurologic Syndrome in Patients With Wilson's Disease With Initial Penicillamine TherapyArchives of Neurology, 1987
- The Treatment of Wilson's Disease with Zinc. IV. Efficacy Monitoring Using Urine and Plasma CopperExperimental Biology and Medicine, 1987
- Treatment of Wilson’s Disease with Zinc II. Validation of Oral 64Copper with Copper BalanceThe Lancet Healthy Longevity, 1986
- Oral Zinc Therapy for Wilson's DiseaseAnnals of Internal Medicine, 1983
- TREATMENT OF WILSON'S DISEASE WITH TRIENTINE (TRIETHYLENE TETRAMINE) DIHYDROCHLORIDEThe Lancet, 1982
- Penicillamine, a new oral therapy for Wilson's diseaseThe American Journal of Medicine, 1956